Formulation and optimisation of raft-forming chewable tablets containing H2 antagonist

The purpose of this research work was to formulate raft-forming chewable tablets of H2 antagonist (Famotidine) using a raft-forming agent along with an antacid- and gas-generating agent. Tablets were prepared by wet granulation and evaluated for raft strength, acid neutralisation capacity, weight va...

Full description

Saved in:
Bibliographic Details
Published in:International Journal of Pharmaceutical Investigation Vol. 2; no. 4; pp. 176 - 182
Main Authors: Prajapati, Shailesh T, Mehta, Anant P, Modhia, Ishan P, Patel, Chhagan N
Format: Journal Article
Language:English
Published: India Medknow Publications & Media Pvt Ltd 01-10-2012
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract The purpose of this research work was to formulate raft-forming chewable tablets of H2 antagonist (Famotidine) using a raft-forming agent along with an antacid- and gas-generating agent. Tablets were prepared by wet granulation and evaluated for raft strength, acid neutralisation capacity, weight variation, % drug content, thickness, hardness, friability and in vitro drug release. Various raft-forming agents were used in preliminary screening. A 2(3) full-factorial design was used in the present study for optimisation. The amount of sodium alginate, amount of calcium carbonate and amount sodium bicarbonate were selected as independent variables. Raft strength, acid neutralisation capacity and drug release at 30 min were selected as responses. Tablets containing sodium alginate were having maximum raft strength as compared with other raft-forming agents. Acid neutralisation capacity and in vitro drug release of all factorial batches were found to be satisfactory. The F5 batch was optimised based on maximum raft strength and good acid neutralisation capacity. Drug-excipient compatibility study showed no interaction between the drug and excipients. Stability study of the optimised formulation showed that the tablets were stable at accelerated environmental conditions. It was concluded that raft-forming chewable tablets prepared using an optimum amount of sodium alginate, calcium carbonate and sodium bicarbonate could be an efficient dosage form in the treatment of gastro oesophageal reflux disease.
AbstractList The purpose of this research work was to formulate raft-forming chewable tablets of H2 antagonist (Famotidine) using a raft-forming agent along with an antacid- and gas-generating agent. Tablets were prepared by wet granulation and evaluated for raft strength, acid neutralisation capacity, weight variation, % drug content, thickness, hardness, friability and in vitro drug release. Various raft-forming agents were used in preliminary screening. A 2(3) full-factorial design was used in the present study for optimisation. The amount of sodium alginate, amount of calcium carbonate and amount sodium bicarbonate were selected as independent variables. Raft strength, acid neutralisation capacity and drug release at 30 min were selected as responses. Tablets containing sodium alginate were having maximum raft strength as compared with other raft-forming agents. Acid neutralisation capacity and in vitro drug release of all factorial batches were found to be satisfactory. The F5 batch was optimised based on maximum raft strength and good acid neutralisation capacity. Drug-excipient compatibility study showed no interaction between the drug and excipients. Stability study of the optimised formulation showed that the tablets were stable at accelerated environmental conditions. It was concluded that raft-forming chewable tablets prepared using an optimum amount of sodium alginate, calcium carbonate and sodium bicarbonate could be an efficient dosage form in the treatment of gastro oesophageal reflux disease.
PURPOSEThe purpose of this research work was to formulate raft-forming chewable tablets of H2 antagonist (Famotidine) using a raft-forming agent along with an antacid- and gas-generating agent. MATERIALS AND METHODSTablets were prepared by wet granulation and evaluated for raft strength, acid neutralisation capacity, weight variation, % drug content, thickness, hardness, friability and in vitro drug release. Various raft-forming agents were used in preliminary screening. A 2(3) full-factorial design was used in the present study for optimisation. The amount of sodium alginate, amount of calcium carbonate and amount sodium bicarbonate were selected as independent variables. Raft strength, acid neutralisation capacity and drug release at 30 min were selected as responses. RESULTSTablets containing sodium alginate were having maximum raft strength as compared with other raft-forming agents. Acid neutralisation capacity and in vitro drug release of all factorial batches were found to be satisfactory. The F5 batch was optimised based on maximum raft strength and good acid neutralisation capacity. Drug-excipient compatibility study showed no interaction between the drug and excipients. Stability study of the optimised formulation showed that the tablets were stable at accelerated environmental conditions. CONCLUSIONIt was concluded that raft-forming chewable tablets prepared using an optimum amount of sodium alginate, calcium carbonate and sodium bicarbonate could be an efficient dosage form in the treatment of gastro oesophageal reflux disease.
Author Prajapati, Shailesh T
Modhia, Ishan P
Patel, Chhagan N
Mehta, Anant P
AuthorAffiliation 1 Department of Pharmaceutical Chemistry, Shri Sarvajanik Pharmacy College, Gujarat, India
Department of Pharmaceutics and Pharmaceutical Technology, Shri Sarvajanik Pharmacy College, Gujarat, India
AuthorAffiliation_xml – name: 1 Department of Pharmaceutical Chemistry, Shri Sarvajanik Pharmacy College, Gujarat, India
– name: Department of Pharmaceutics and Pharmaceutical Technology, Shri Sarvajanik Pharmacy College, Gujarat, India
Author_xml – sequence: 1
  givenname: Shailesh T
  surname: Prajapati
  fullname: Prajapati, Shailesh T
  organization: Department of Pharmaceutics and Pharmaceutical Technology, Shri Sarvajanik Pharmacy College, Gujarat, India
– sequence: 2
  givenname: Anant P
  surname: Mehta
  fullname: Mehta, Anant P
– sequence: 3
  givenname: Ishan P
  surname: Modhia
  fullname: Modhia, Ishan P
– sequence: 4
  givenname: Chhagan N
  surname: Patel
  fullname: Patel, Chhagan N
BackLink https://www.ncbi.nlm.nih.gov/pubmed/23580933$$D View this record in MEDLINE/PubMed
BookMark eNpVUMFOwzAMjRCIjbE7J9Qjl44kTpv0goQmxpAmcQG0W5Wm6RbUJqVJQfw9nTYm8MG2nu33bF-gU-usRuiK4BkjGG4pBRxnHNYzgtNMiBM0PkAETo85rEdo6v07HoxlgtP0HI0oJAJnAGP0tnBd09cyGGcjacvItcE0xu8BV0WdrEJcDU3GbiK11V-yqHUUdj74SDkbpLG72pIO80FunDU-XKKzStZeTw9xgl4XDy_zZbx6fnya36_ilhACccKBKQFSC6a0SBItMiWkVlVR0gxEtttZZQQ4pkpWieSq4CXXwBgrCkYkTNDdnrfti0aXStvQyTpvO9PI7jt30uT_K9Zs8437zCElIgUYCG4OBJ376LUP-XC80nUtrXa9zwnQlFORYj60Xv_VOor8PhN-AKiZezI
ContentType Journal Article
Copyright Copyright: © International Journal of Pharmaceutical Investigation 2012
Copyright_xml – notice: Copyright: © International Journal of Pharmaceutical Investigation 2012
DBID NPM
7X8
5PM
DOI 10.4103/2230-973X.106988
DatabaseName PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle PubMed
MEDLINE - Academic
DatabaseTitleList PubMed
MEDLINE - Academic
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 2230-9713
EndPage 182
ExternalDocumentID 23580933
Genre Journal Article
GroupedDBID 53G
AAKDD
ABDBF
ABXLX
ACGFS
ADBBV
ADRAZ
AEGXH
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
DIK
EBD
EOJEC
ESX
GX1
H13
HYE
IAO
IHR
ITC
KQ8
M48
MK0
M~E
NPM
OBODZ
OK1
PGMZT
RMW
RPM
TUS
W3E
7X8
5PM
ID FETCH-LOGICAL-p1113-5734c83ae84ce855e89c8aecfbd293890004c913702caf5a7cb7d7e3444bb41a3
IEDL.DBID RPM
ISSN 2230-973X
IngestDate Tue Sep 17 21:11:15 EDT 2024
Sat Aug 17 03:15:03 EDT 2024
Sat Sep 28 08:02:50 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 4
Keywords sodium alginate
raft-forming agent
famotidine
texture analyzer
raft strength
Acid neutralisation capacity
Language English
License This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-p1113-5734c83ae84ce855e89c8aecfbd293890004c913702caf5a7cb7d7e3444bb41a3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3618633/
PMID 23580933
PQID 1326728607
PQPubID 23479
PageCount 7
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_3618633
proquest_miscellaneous_1326728607
pubmed_primary_23580933
PublicationCentury 2000
PublicationDate 2012-Oct
PublicationDateYYYYMMDD 2012-10-01
PublicationDate_xml – month: 10
  year: 2012
  text: 2012-Oct
PublicationDecade 2010
PublicationPlace India
PublicationPlace_xml – name: India
PublicationTitle International Journal of Pharmaceutical Investigation
PublicationTitleAlternate Int J Pharm Investig
PublicationYear 2012
Publisher Medknow Publications & Media Pvt Ltd
Publisher_xml – name: Medknow Publications & Media Pvt Ltd
References 19925256 - Drug Dev Ind Pharm. 2010 May;36(5):614-23
18097809 - Drug Dev Ind Pharm. 2007 Dec;33(12 ):1350-61
10848650 - Aliment Pharmacol Ther. 2000 Jun;14(6):669-90
3201128 - Scand J Gastroenterol. 1988 Oct;23 (8):920-4
11084248 - Int J Pharm. 2000 Nov 19;209(1-2):79-85
15814238 - Int J Pharm. 2005 Apr 27;294(1-2):137-47
References_xml
SSID ssj0000498726
Score 1.8616462
Snippet The purpose of this research work was to formulate raft-forming chewable tablets of H2 antagonist (Famotidine) using a raft-forming agent along with an...
PURPOSEThe purpose of this research work was to formulate raft-forming chewable tablets of H2 antagonist (Famotidine) using a raft-forming agent along with an...
SourceID pubmedcentral
proquest
pubmed
SourceType Open Access Repository
Aggregation Database
Index Database
StartPage 176
SubjectTerms Original
Title Formulation and optimisation of raft-forming chewable tablets containing H2 antagonist
URI https://www.ncbi.nlm.nih.gov/pubmed/23580933
https://search.proquest.com/docview/1326728607
https://pubmed.ncbi.nlm.nih.gov/PMC3618633
Volume 2
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV09T8MwELUoEwvim_IlI6FOTZvEduyMCFp1AVWioG6V7TgCRNOKtEL8e-7yAS1iYsmQxFJydnLv5HfvEXIVJVqmsXVeIljocQ6flBLCeqEFeBEY4WuJ3ciDB3k_Vrc9lMkRdS9MQdq35qWTvU072ctzwa2cT2235ol1h3c3DEXeGes2SAOw4UqJ_lpCXiULmzXIfL4XSzYutyd54LPu9zkoW6NYoV0fNotiXf8XxvxNlVzJPf0dsl2BRnpdPtwu2XDZHmkNS9XpzzYd_TRR5W3aosMfPerPffLUB1xauXRRnSV0Br-JaUXjobOUvut04SF4hTRGYRI_sJ2KLvC4yCmS2UsbCToIYTxuY6Hc7gF57PdGNwOvslPw5ugn7wnJuFVMO8XRq1Q4FVulnU1NAjlfoXsot3HApB9anQotrZGJdIxzbgwPNDskm9ksc8eEhirlJnCQ_aXlPk-NiLhLXRhHsXEAUJrksg7lBN4H9yB05mbLfALFbyRDFfmySY7K0E7mpa7GpJ6IJpFrQf--AaWw16_ACikksasVcfLvkadkC6BQWNL0zsjm4n3pzkkjT5YXxfL6Al4y1hc
link.rule.ids 230,315,729,782,786,887,27933,27934,53800,53802
linkProvider National Library of Medicine
linkToHtml http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3LTuMwFL0aYDFsGJjh0eHlkUasCE1iO3aWCKg64qFKUxC7yHYcUUTTirYa8fdzb5LyEis2WSSxlOjE8bnyuecA_E5yo4rU-SCXPA6EwCmlpXRB7JBeRFaGRlE3cvevurrVp2dkkyPnvTCVaN_ZwVH5MDwqB3eVtnI8dO25TqzduzzhZPLOeXsBlnC-huGrIv2-Jr1aVUFruPaFQar4bb1BKaKQt5_PYeGapJoC-6hdlCr7j1jme7Hkq9Wn8-2Tz70KKw3dZMf15TX44svvcNCr_aqfDln_pf1qcsgOWO_FyfrpB9x0kNE2-V7MlDkb4Q9m2AiA2Khgj6aYBkR7cQFkCP8_asRiUzpOJ4xk8HUABevGOJ42wMiodx2uO2f9k27QBDEEY0qiD6TiwmluvBaUciq9Tp023hU2R7agKXdUuDTiKoydKaRRzqpceS6EsFZEhm_AYjkq_RawWBfCRh55g3IiFIWVifCFj9MktR6pTQt-zSHI8H1o98KUfjSbZFg2JyrWSahasFlDko1rR45sDmAL1Buwnm8gE-23VxCjyky7weTnp0fuw9du__Iiu_hzdb4Ny0io4lrstwOL08eZ34WFST7bqz7R_zM5650
linkToPdf http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1NT9wwEB0VKlW90EK_tqVgpIoTIYntxM4RAatFLWglaMUtsh1bUHWzK3ZXiH_fmSS7QMWpXHJIbCnR2Jk38pv3AL7llVGhcD6qMsEjKXFL6SxzEXcIL1KbJUZRN_LgXJ1d6qNjkslZWn01pH1nr_frP6P9-vqq4VZORi5e8MTi4emhIJF3IeJJFeIVeIl7NuEPCvXfLfDVqjFbw_yXRIUSl-0hpUwTES_vYfGaF5pM-6hllKr7p5Dmv4TJBxmo_-YZ7_4W1jrYyQ7aIevwwtcbsDtsdavv9tjFfRvWdI_tsuG9ovXdO_jVR2Tb-XwxU1dsjD-aUUcEYuPAbkyYRQR_MREyXAa31JDFZnSdTRnR4VsjCjbgOJ8Owkiw9z387B9fHA6izpAhmpAjfZQpIZ0WxmtJbqeZ14XTxrtgK0QNmvxHpStSoRLuTMiMclZVygsppbUyNeIDrNbj2n8CxnWQNvWIH5STiQw2y6UPnhd5YT1CnB7sLMJQ4vfQKYap_Xg-LbF8zhXXeaJ68LENSzlplTnKRRB7oB4FbDmAxLQfP8E4NaLaXVw-__fMbXg1POqXP07Ovn-B14ireMv524TV2c3cf4WVaTXfalbpX6B97h0
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Formulation+and+optimisation+of+raft-forming+chewable+tablets+containing+H2+antagonist&rft.jtitle=International+Journal+of+Pharmaceutical+Investigation&rft.au=Prajapati%2C+Shailesh+T&rft.au=Mehta%2C+Anant+P&rft.au=Modhia%2C+Ishan+P&rft.au=Patel%2C+Chhagan+N&rft.date=2012-10-01&rft.issn=2230-973X&rft.volume=2&rft.issue=4&rft.spage=176&rft.epage=182&rft_id=info:doi/10.4103%2F2230-973X.106988&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2230-973X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2230-973X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2230-973X&client=summon